Drugs / PanAd3-RSV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01805921 | May 2013 → Aug 2015 | respiratory syncytial virus infectious disease | ReiThera Srl | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PanAd3-RSV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01805921 ↗ |
| Modality | Vaccine | “novel genetic viral-vectored vaccine candidates PanAd3-RSV and modified vaccinia virus Ankara (MVA)-RSV” PMID 26510727 ↗ Oct 2015 |
| Route | Intranasal | “PanAd3-RSV given intra-nasally (high dose)” NCT01805921 ↗ |